Advertisement

The Fibrinolytic Enzyme System

  • Derek Ogston

Abstract

An outline of the fibrinolytic enzyme system was provided in Chapter 1. In this chapter the properties of the individual components of the system are described with an account of their interaction to culminate in the physiological dissolution of fibrin.

Keywords

Fibrinolytic Activity Tissue Activator Molecular Weight Form High Molecular Weight Form Thrombosis Research 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aasted, B., (1980) ‘Purification and characterization of human vascular plasminogen activator’, Biochimica et Biophysica Acta, 621, 241–54Google Scholar
  2. Abiko, Y., Iwamoto, M. and Tomikawa, M. (1969) ‘Plasminogen-plasmin system. V. A stoichiometric equilibrium complex of plasminogen and a synthetic inhibitor’, Biochimica et Biophysica Acta, 185, 424–31Google Scholar
  3. Alagille, D. and Soulier, J.P. (1956) ‘Action des enzymes proteolytiques sur le sang total “in vitro”. Modifications des facteurs de coagulation et du complement’, La Semaine des Höpitaux de Paris, 32, 355–9Google Scholar
  4. Albrechtsen, O.K. (1957) ‘The fibrinolytic activity of human tissues’, British Journal of Haematology, 3, 284–91Google Scholar
  5. Albrechtsen, O.K. and Thaysen, J.H. (1955/56) ‘Fibrinolytic activity in human saliva’, Acta Physiologica Scandinavia, 35, 138–45Google Scholar
  6. Albrechtsen, O.K., Storm, O. and Claasen, M. (1958) ‘Fibrinolytic activity in some human body fluids’, Scandinavian Journal of Clinical and Laboratory Investigation, 10, 310–8Google Scholar
  7. Alkjaersig, N. (1961) ‘The antifibrinolytic activity of platelets’, in S.A. Johnson, R.W. Monto, J.W. Rebuck and R.C. Horn (eds.) Blood Platelets, Little, Brown, Boston, pp. 329–36Google Scholar
  8. Alkjaersig, N., Fletcher, A.P. and Sherry, S. (1958) ‘The activation of human plasminogen. I. Spontaneous activation in glycerol’, Journal of Biological Chemistry, 233, 81–5Google Scholar
  9. Alkjaersig, N., Fletcher, A.P. and Sherry, S. (1959) ‘The mechanism of clot dissolution by plasmin’, Journal of Clinical Investigation. 38, 1086–95Google Scholar
  10. Allen, R.A. and Pepper, D.S. (1981) ‘Isolation and properties of human vascular plasminogen activator’, Thrombosis and Haemostasis, 45, 43–50Google Scholar
  11. Ambrus, CM. and Markus, G. (1960) ‘Plasmin-antiplasmin complex as a reservoir of fibrinolytic enzyme’, American Journal of Physiology, 199, 491–4Google Scholar
  12. Aoki, N. (1974) ‘Preparation of plasminogen activator from vascular tree of human cadavers. Its comparison with urokinase’, Journal of Biochemistry, 75, 731–41Google Scholar
  13. Aoki, N. and von Kaulla, K.N. (1971a) ‘The extraction of vascular activator from human cadavers. Some of its properties’, American Journal of Clinical Pathology, 55, 171–9Google Scholar
  14. Aoki, N. and von Kaulla, K.N. (1971b) ‘Dissimilarity of human plasminogen activator and urokinase’, Journal of Laboratory and Clinical Medicine, 78, 354–62Google Scholar
  15. Aoki, N. and von Kaulla, K.N. (1971c) ‘Human serum plasminogen antiactivator: its distinction from antiplasmin’, American Journal of Physiology, 220, 1137–45Google Scholar
  16. Aoki, N. and Kawano, T. (1972) ‘Inhibition of plasminogen activators by naturally occurring inhibitors in man’, American Journal of Physiology, 223, 1334–7Google Scholar
  17. Aoki, N. and Yamanaka, T. (1978) ‘The a2-plasmin inhibitor levels in liver disease’, Clinica Chimica Acta, 84, 99–105Google Scholar
  18. Aoki, N., Moroi, M. and Tachiya, K. (1978) ‘Effects of oc2-plasmin inhibitor on fibrin clot lysis. Its comparison with a2-macroglobulin’, Thrombosis and Haemostasis, 39, 22–31Google Scholar
  19. Astedt, B. (1975) ‘Fibrinolysis in cultured cells’, Thrombosis et Diathesis Haemorrhagica, 34, 644–7Google Scholar
  20. Astedt, B. (1979) ‘No crossreaction between circulating plasminogen activator and urokinase’, Thrombosis Research, 14, 535–9Google Scholar
  21. Astedt, B., Pandolfi, M. and Nilsson, I.M. (1972) ‘Inhibitory effect of placenta on plasminogen activation in human organ culture’, Proceedings of the Society for Experimental Biology and Medicine, 139, 1421–4Google Scholar
  22. Astedt, B., Barlow, G. and Holmberg, L. (1977) ‘Time-related release of various molecular forms of urokinase in tissue culture’, Thrombosis Research, 11, 149–53Google Scholar
  23. Astrup, T. and Permin, P.M. (1947) ‘Fibrinolysis in the animal organism’, Nature, 759,681–2Google Scholar
  24. Astrup, T. and Rosa, A.T. (1974) ‘A plasminogen proactivator-activator system in human blood effective in the absence of Hageman factor’, Thrombosis Research, 4, 609–13Google Scholar
  25. Astrup, T. and Stage, A. (1952) ‘Isolation of soluble fibrinolytic activator from animal tissue’, Nature, 170, 929Google Scholar
  26. Astrup, T. and Sterndorff, I. (1953) ‘A fibrinolytic system in human milk’, Proceedings of the Society for Experimental Biology and Medicine, 84, 605–8Google Scholar
  27. Astrup, T., Henrichsen, J. and Kwaan, H.C. (1967) ‘Protease content and fibrinolytic activity of human leucocytes’, Blood, 29, 134–8Google Scholar
  28. Bachmann, F., Fletcher, A.P., Alkjaersig, N. and Sherry, S. (1964) ‘Partial purification and properties of the plasminogen activator from pig heart’, Biochemistry, 3, 1578–85Google Scholar
  29. Back, N., Ambrus, J.L. and Mink, LB. (1961) ‘Distribution and fate of I131-labelled components of the fibrinolysin system’, Circulation Research, 9, 1208–16Google Scholar
  30. Bagdasarian, A. and Colman, R.W. (1978) ‘Subcellular localization and purification of platelet a l-antitrypsin’, Blood, 51, 139–56Google Scholar
  31. Bang, N.U., Chang, M.L., Mattler, L.E., Burek, P.J., Van Frank, R.M., Zimmermann, R.E., Marks, C.A. and Boxer, L.J. (1981) ‘Monocyte macrophage-mediated catabolism of fibrinogen and fibrin’, Annals of the New York Academy of Sciences, 370, 568–87Google Scholar
  32. Barlow, G.H. and Lazer, L. (1972) ‘Characterization of the plasminogen activator isolated from human embryo kidney cells: comparison with urokinase’, Thrombosis Research, 1, 201–7Google Scholar
  33. Barnhart, M.I. and Riddle, J.M. (1963) ‘Cellular localisation of Profibrinolysin (plasminogen)’, Blood, 21, 306–21Google Scholar
  34. Barrett, A.J. and Starkey, P.M. (1973) ‘The interaction of the oc2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism’, Biochemical Journal, 133, 709–24Google Scholar
  35. Bennett, N.B. (1967) ‘Inhibitors of plasminogen activation in human serum’, Thrombosis et Diathesis Haemorrhagica, 17, 12–22Google Scholar
  36. Bernik, M.B. (1973) ‘Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition’, Journal of Clinical Investigation, 52, 823–34Google Scholar
  37. Bernik, M.B. and Kwaan, H.C. (1967) ‘Origin of fibrinolytic activity in cultures of the human kidney’, Journal of Laboratory and Clinical Medicine, 70, 650–61Google Scholar
  38. Bernik, M.B. and Kwaan, H.C. (1971) ‘Inhibitors of fibrinolysis in human tissues in culture’, American Journal of Physiology, 221, 916–21Google Scholar
  39. Bernik, M.B., White, W.F., Oller, E.P. and Kwaan, H.C. (1974) ‘Immunological identity of plasminogen activator in human urine, heart, blood vessels, and tissue culture’, Journal of Laboratory and Clinical Medicine, 84, 546–58Google Scholar
  40. Bernik, M B., Rijken, D.C. and Wijngaards, G. (1979) ‘Production of immunologically distinct plasminogen activators by human tissue in culture’, Thrombosis and Haemostasis, 42, 414Google Scholar
  41. Bernik, M.B., Wijngaards, G. and Rijken, D.C. (1981) ‘Production by human tissues in culture of immunologically distinct, multiple molecular weight forms of plasminogen activators’, Annals of the New York Academy of Sciences, 370, 592–608Google Scholar
  42. Bilezikian, S. and Nossel, H.L. (1977) ‘Unique pattern of fibrinogen cleavage by human leucocyte proteases’, Blood, 50, 21–8Google Scholar
  43. Binder, B.R., Spragg, J. and Austen, K.F. (1979) ‘Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates’, Journal of Biological Chemistry, 254, 1998–2003Google Scholar
  44. Binder, B.R., Reissert, G. and Beckmann, R. (1981) ‘Isolation and characterization of a plasminogen activator (PA) from human myocardial tissue’, Thrombosis and Haemostasis, 46, 11Google Scholar
  45. Brakman, P. and Astrup, T. (1963) ‘Selective inhibition in human pregnancy blood of urokinase induced fibrinolysis’, Scandinavian Journal of Clinical and Laboratory Investigation, 15, 603–9Google Scholar
  46. Brower, M.S. and Harpel, P.C. (1982) ‘Proteolytic cleavage and inactivation of a2-plasmin inhibitor and CI inactivator’, Journal of Biological Chemistry, 257, 9849–54Google Scholar
  47. Camiolo, S.M., Thorsen, S. and Astrup, T. (1971) ‘Fibrinogenolysis and fibrinolysis with tissue plasminogen activator’, Proceedings of the Society for Experimental Biology and Medicine, 38, 271–80Google Scholar
  48. Cartwright, T. (1974) ‘Partial purification of a specific plasminogen activator from porcine parotid glands’, Thrombosis et Diathesis Haemorrhagica, 31, 403–14Google Scholar
  49. Cash, J.D., Woodfield, D.G. and Allan, A.G.E. (1970) ‘Adrenergic mechanisms in the systemic plasminogen activator response to adrenaline in man’, British Journal of Haematology, 18, 487–94Google Scholar
  50. Christensen, U. and Clemmensen, I. (1977) ‘Kinetic properties of the primary inhibitor of plasmin from human plasma’, Biochemical Journal, 163, 389–91Google Scholar
  51. Christensen, U. and Clemmensen, I. (1978) ‘Purification and reaction mechanisms of the primary inhibitor of plasmin from human plasma’, Biochemical Journal, 775,635–41Google Scholar
  52. Christensen, U. and Mullertz, S. (1974) ‘Mechanism of reaction of human plasmin with a-N-benzoyl-L-argininenitroanilide’, Biochimica et Biophysica Acta, 334, 187–98Google Scholar
  53. Claeys, H. and Vermylen, J. (1974) ‘Physico-chemical and proenzyme properties of NH2-terminal glutamic acid and NH2-terminal lysine human plasminogen’, Biochimica et Biophysica Acta, 343, 351–9Google Scholar
  54. Clemmensen, I. (1978) ‘Inhibition of urokinase by complex formation with human antithrombin III in absence and presence of heparin’, Thrombosis and Hemostasis, 39, 616–23Google Scholar
  55. Clemmensen, I. (1979) ‘Different molecular forms of a2-antiplasmin’, in D. Collen, B. Wiman and M. Verstraete (eds.) The Physiological Inhibitors of Coagulation and Fibrinolysis, Elsevier/North Holland, Biomedical Press, Amsterdam, pp. 131–6Google Scholar
  56. Clemmensen, I. and Christensen, U. (1976) ‘Inhibition of urokinase by complex formation with human alphat-antitrypsin’, Biochimica et Biophysica Acta, 429, 591–9Google Scholar
  57. Coeugnet, E. (1979) ‘Lymphokines and thrombosis. Effect of lymphokines on fibrinolysis. Release of fibrinolytic activity by human leucocytes stimulated with lymphokines’, Thrombosis and Haemostasis, 42, 1240–7Google Scholar
  58. Cohen, A.B. (1973) ‘Mechanism of action of a-1-antitrypsin’, Journal of Biological Chemistry, 248, 7055–9Google Scholar
  59. Cole, E.R. and Bachmann, F.W. (1977) ‘Purification and properties of a plasminogen activator from pig heart’, Journal of Biological Chemistry, 252, 3729–37Google Scholar
  60. Collen, D. (1976) ‘Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma’, European Journal of Biochemistry, 69, 209–16Google Scholar
  61. Collen, D. and de Maeyer, L. (1975) ‘Molecular biology of human plasminogen I. Physicochemical properties and microheterogeneity’, Thrombosis et Diathesis Haemorrhagica, 34, 396–402Google Scholar
  62. Collen, D. and Verstraete, M. (1975) ‘Molecular biology of human plasminogen. II. Metabolism in physiological and some pathological conditions in man’, Thrombosis et Diathesis Haemorrhagica, 34, 403–8Google Scholar
  63. Collen, D. and Wiman, B. (1979) ‘Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma’, Blood, 53, 313–24Google Scholar
  64. Collen, D., Tytgat, G., Claeys, H., Verstraete, M. and Wallen, P. (1972) ‘Metabolism of plasminogen in healthy subjects: effect of tranexamic acid’, Journal of Clinical Investigation, 51, 1310–8Google Scholar
  65. Collen, D., Kudryk, B., Hessel, B. and Blombäck, B. (1975) ‘Primary structure of human fibrinogen and fibrin. Isolation and partial characterization of chains of fragment D’, Journal of Biological Chemistry, 250, 5808–17Google Scholar
  66. Collen, D., Semeraro, N., Telesforo, P. and Verstraete, M. (1978) ‘Inhibition of plasmin by antithrombin-heparin complex. II. During thrombolytic therapy in man’, British Journal of Haematology, 39, 101–10Google Scholar
  67. Colman, R.W. (1969) ‘Activation of plasminogen by human plasma kallikrein’, Biochemical and Biophysical Research Communications, 35, 273–9Google Scholar
  68. Crawford, G.P.M. and Ogston, D. (1974) ‘The influence of a-l-antitrypsin on plasmin, urokinase and Hageman factor cofactor’, Biochimica et Biophysica Acta, 354, 107–13Google Scholar
  69. Crawford, G.P.M. and Ogston, D. (1975) ‘The action of antithrombin III on plasmin and activators of plasminogen’, Biochimica et Biophysica Acta, 391, 189–92Google Scholar
  70. Donaldson, V.H. (1960) ‘Effect of plasmin in vitro on clotting factors in plasma’, Journal of Laboratory and Clinical Medicine, 56, 644–51Google Scholar
  71. Dooijewaard, G., van Iersel, J.J.L., Los, P. and Kluft, C. (1982) ‘The intrinsic system of fibrinolysis: identification and partial purification of plasma urokinase’, Haemostasis, 11, Suppl. 1, 8Google Scholar
  72. Doolittle, R.F., Cassman, K.G., Cottrell, B.A., Friezner, S.J. and Takagi, T. (1977) ‘Amino acid sequence on the a-chain of human fibrinogen. Covalent structure of the a-chain portion of fragment D’, Biochemistry, 16, 1710–5Google Scholar
  73. Dosne, A.M., Dupuy, E. and Bodevin, E. (1978) ‘Production of a fibrinolytic inhibitor in cultured endothelial cells derived from human umbilical vein’, Thrombosis Research, 12, 371–378Google Scholar
  74. Ekert, H., Friedlander, L. and Hardisty, R.M. (1970) ‘The role of platelets in fibrinolysis. Studies on the plasminogen activator and anti-plasmin activity of platelets’, British Journal of Haematology, 18, 575–84Google Scholar
  75. Eriksson, M. and Saldeen, T. (1980) ‘Venous macrothromboembolism in an unselected autopsy material and its relation to antiplasmin activity in the vessel wall’, Thrombosis Research, 20, 555–61Google Scholar
  76. Fearnley, G.R. and Tweed, J.M. (1953) ‘Evidence of an active fibrinolytic enzyme in the plasma of normal people with observations on inhibition associated with the presence of calcium’, Clinical Science, 12, 81–9Google Scholar
  77. Gaffney, P.J. (1973) “Subunit relationships between fibrinogen and fibrin degradation products”, Thrombosis Research, 2, 201–18Google Scholar
  78. Gaffney, P.J. and Brasher, M. (1973) ‘Subunit structure of the plasmin-induced degradation products of crosslinked fibrin’, Biochimica et Biophysica Acta, 295,308–13Google Scholar
  79. Gaffney, P.J. and Dubos, P. (1971) ‘A structural aspect of human fibrinogen suggested by its plasmin degradation’, FEBS Letters, 15, 13–6Google Scholar
  80. Gaffney, P.J., Lane, D.A. and Brasher, M. (1975) ‘Soluble high-molecular-weight E fragments in the plasmin-induced degradation products of cross-linked fibrin’, Clinical Science and Molecular Medicine, 49, 149–56Google Scholar
  81. Gaffney, P.J., Joe, F. and Mahmoud, M. (1980) ‘Giant fibrin fragments derived from crosslinked fibrin: structure and clinical implication’, Thrombosis Research, 20, 647–62Google Scholar
  82. Gallimore, M.J. (1975) ‘Serum inhibitors of fibrinolysis’, British Journal of Haematology, 31, 217–31Google Scholar
  83. Ganguly, P. (1972) ‘A low molecular weight antiplasmin of human blood platelets’, Clinica Chimica Acta, 39, 466–8Google Scholar
  84. Ganrot, P.O. (1967) ‘Inhibition of plasmin activity by a2-macroglobulin’, Clinica Chimica Acta, 16, 328–30Google Scholar
  85. Gans, H. and Tan, B.H. (1967) ‘a,-antitrypsin, an inhibitor for thrombin and plasmin’, Clinica Chimica Acta, 7, 111–7Google Scholar
  86. Goldsmith, G.H., Saito, H. and Ratnoff, O.D. (1978) ‘The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments’, Journal of Clinical Investigation, 62, 54–60Google Scholar
  87. Goldstein, I.M., Wunschmann, B., Astrup, T. and Henderson, E.S. (1971) ‘Effects of bacterial endotoxin on the fibrinolytic activity of normal human leukocytes’, Blood, 37, 447–53Google Scholar
  88. Gramse, M., Bingenheimer, C, Schmidt, W., Egbring, R. and Havemann, K. (1978) ‘Degradation products of fibrinogen by elastase-like neutral protease from human granulocytes. Characterization and effects on blood coagulation in vitro’, Journal of Clinical Investigation, 61, 1027–33Google Scholar
  89. Granelli-Piperno, A., Vassalli, J.-D. and Reich, E. (1977) ‘Secretion of plasminogen activator by human polymorphonuclear leukocytes. Modulation by glucocorticoids and other effectors’, Journal of Experimental Medicine, 146, 1693–706Google Scholar
  90. Grasi, B., Jörg, M. and Binder, B.R. (1982) ‘Isolation of a plasminogen activator from human plasma by affinity chromatography on anti-urokinase-Sepharose, partial purification of the enzyme’, Haemostasis, 11, Suppl. 1, 9Google Scholar
  91. Groskopf, W.R., Hsieh, B., Summaria, L. and Robbins, K.C. (1968) ‘The specificity of human plasmin on the B-chain of oxidised bovine insulin’, Biochimica et Biophysica Acta, 168, 376–73Google Scholar
  92. Gurewich, V., Hyde, E. and Lipinski, B. (1975) ‘The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs’, Blood, 46, 555–65Google Scholar
  93. Harker, L.A., Schmer, G. and Slichter, S.J. (1972) ‘Plasminogen kinetics in man’, Abstracts IIrd Congress of the International Society of Thrombosis and Haemostasis, p. 294Google Scholar
  94. Harpel, P.C. (1970) ‘CI inactivator inhibition by plasmin’, Journal of Clinical Investigation, 49, 568–75Google Scholar
  95. Harpel, P.C. (1973) ‘Studies on human plasma a2-macroglobulin-enzyme interactions. Evidence for proteolytic modification of the subunit chain structure’, Journal of Experimental Medicine, 138, 508–21Google Scholar
  96. Harpel, P.C. and Cooper, N.R. (1975) ‘Studies on plasma CI inactivator-enzyme interactions. I. Mechanisms on interaction with Cls, plasmin and trypsin’, Journal of Clinical Investigation, 55, 593–604Google Scholar
  97. Harpel, P.C. and Mosesson, M.W. (1973) ‘Degradation of human fibrinogen by plasma oc2-macroglobulin-enzyme complexes’, Journal of Clinical Investigation, 52, 2175–84Google Scholar
  98. Haupt, H. and Heimburger, N. (1972) ‘Humanserumproteine mit holer Affinität zu Carboxymethylcellulose, I’, Hoppe-Seyler’s Zeitschrift fur Physiologische Chemie, 353, 1125–32Google Scholar
  99. Haverkate, F. and Timan, G. (1977) ‘Protective effect of calcium in plasmin degradation of fibrinogen and fibrin fragment D’, Thrombosis Research, 10, 803–12Google Scholar
  100. Hayes, M.L. and Castellino, F.J. (1979a) ‘Carbohydrate of the human plasminogen variants. I. Carbohydrate composition, glycopeptide isolation, and characterization’, Journal of Biological Chemistry, 254, 8768–71Google Scholar
  101. Hayes, M.L. and Castellino, F.J. (1979b) ‘Carbohydrate of the human plasminogen variants. II. Structure of the asparagine-linked oligosaccharide unit’, Journal of Biological Chemistry, 254, 2–6Google Scholar
  102. Hayes, M.L. and Castellino, F.J. (1979c) ‘Carbohydrate of the human plasminogen variants. III. Structure of the O-glycosidically linked oligosaccharide unit’, Journal of Biological Chemistry, 254, 48–59Google Scholar
  103. Hedner, U. (1973) ‘Studies on an inhibitor of plasminogen activation in human serum’, Thrombosis et Diathesis Haemorrhagica, 30, 414–24Google Scholar
  104. Hedner, U. and Martinsson, G. (1978) ‘Inhibition of activated Hageman factor by an inhibitor of the plasminogen activation’, Thrombosis Research, 12, 1015–23Google Scholar
  105. Hedner, U., Nilsson, I.M. and Jacobsen, CD. (1970) ‘Demonstration of low content of fibrinolytic inhibitors in individuals with high fibrinolytic capacity’, Scandinavian Journal of Clinical and Laboratory Investigation, 25, 329–36Google Scholar
  106. Heide, K., Heimburger, N. and Haupt, H. (1965) ‘An inter-alpha trypsin inhibitor of human serum’, Clinica Chimica Acta, 11, 82–5Google Scholar
  107. Heimburger, N., Haupt, H., Kranz, T. and Baudner, S. (1972) ‘Humanserumproteine mit holer Affinität zu Carboxymethylcellulose, II’, Hoppe-Seyler’s Zeitschrift fur Physiologische Chemie, 353, 1133–40Google Scholar
  108. Henschen, A. and Lottspeich, F. (1982) ‘Structural characterisation of different molecular weight forms of urokinase’, Haemostasis, 11, Suppl. 1, 54Google Scholar
  109. Herbert, R.J., Ogston, D. and Douglas, A.S. (1972) ‘Further purification and properties of Hageman factor cofactor’, Biochimica et Biophysica Acta, 271, 371–7Google Scholar
  110. Hermann, G. and Miescher, P.A. (1965) ‘Differentiation of leucocytic fibrinolytic enzymes from plasmin by the use of plasmatic proteolytic inhibitors’, International Archives of Allergy and Applied Immunology, 27, 346–54Google Scholar
  111. Hessel, B. (1975) ‘On the structure of the COOH-terminal part of the Aa-chain of human fibrinogen’, Thrombosis Research, 7, 75–87Google Scholar
  112. Highsmith, R.F. (1981) ‘Isolation and properties of a plasminogen activator derived from canine vascular tissue’, Journal of Biological Chemistry, 256, 6788–95Google Scholar
  113. Highsmith, R.F. and Kline, D.L. (1971) ‘Kidney: primary source of plasminogen after acute depletion in the cat’, Science, 174, 141–2Google Scholar
  114. Highsmith, R.F. and Rosenberg, R.D. (1974) ‘The inhibition of human plasmin by human antithrombin-heparin cofactor’, Journal of Biological Chemistry, 249, 4335–8Google Scholar
  115. Hijikata, A., Hirata, M. and Kitaguchi, H. (1980) ‘Effect of proteases on plasminogen activator release from isolated perfused dog leg’, Thrombosis Research, 20, 521–31Google Scholar
  116. Hobart, M.J. (1979) ‘Genetic polymorphism of human plasminogen’, Annals of Human Genetics, 42, 419–23Google Scholar
  117. Hochschwender, S.M. and Laursen, R.A. (1981) ‘The lysine binding sites of human plasminogen. Evidence for a critical tryptophan in the binding site of kringle 4’, Journal of Biological Chemistry, 256, 111–726Google Scholar
  118. Högstörp, H. and Saldeen, T. (1982) ‘Rat hepatocytes synthesize alpha2- antiplasmin’, Haemostasis, 11, Suppl. 1, 46Google Scholar
  119. Holmberg, L., Bladh, B. and Astedt, B. (1976) ‘Purification of urokinase by affinity chromatography’, Biochimica et Biophysica Acta, 445, 215–22Google Scholar
  120. Holmberg, L., Leeander, I., Persson, B. and Astedt, B. (1978) ‘An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture’, Biochimica et Biophysica Acta, 544, 128–37Google Scholar
  121. Hoylaerts, M., Rijken, D.C., Lijnen, H.R. and Collen, D. (1982) ‘Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin’, Journal of Biological Chemistry, 257, 2912–9Google Scholar
  122. Hudry-Clergeon, G., Paturel, L. and Suscillon, M. (1974) ‘Identification d’un complexe (D-D)... E dans les produits de degradation de la fibrine bovine stailisee par le facteur XIII’, Pathologie et Biologie (Paris), 22, Suppl., 47–52Google Scholar
  123. Hume, R. (1958) ‘An inhibitory effect of platelets on fibrinolysis’, Scottish Medical Journal, 3, 479–83Google Scholar
  124. Husain, S.S., Lipinski, E. and Gurewich, V. (1981) ‘Rapid purification of a high-affinity plasminogen activator from human blood plasma by specific adsorption on fibrin/Celite’, Proceedings of the National Academy of Sciences, 78, 4625–9Google Scholar
  125. Iatridis, S.G. and Ferguson, J.H. (1962) ‘Active Hageman factor: A plasma lysokinase of the human fibrinolytic system’, Journal of Clinical Investigation, 41, 1277–87Google Scholar
  126. Jedrychowski, A., Parbhoo, S.P. and Hillenbrand, P. (1972) ‘Plasminogen activator in bile during extracorporeal perfusion of pig liver’, Gut, 13, 54–7Google Scholar
  127. Johnson, S.A. and Schneider, C.L. (1953) ‘The existence of antifibrinolysin activity in platelets’, Science, 117, 229–30Google Scholar
  128. Joist, J.H., Niewiarowski, S., Nath, N. and Mustard, J.F. (1976) ‘Platelet antiplasmin: its extrusion during the release reaction, subcellular localization, characterization and relationship to antiheparin in pig platelets’, Journal of Laboratory and Clinical Medicine, 87, 659–69Google Scholar
  129. Kaplan, A.P. and Austen, K.F. (1972) ‘The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator’, Journal of Experimental Medicine, 136, 1378–93Google Scholar
  130. von Kaulla, K.N. and Shettles, L.B. (1953) ‘Relationship between human seminal fluid and the fibrinolytic system’, Proceedings of the Society for Experimental Biology and Medicine, 83, 692–4Google Scholar
  131. Kawano, T., Morimoto, K. and Iemura, Y. (1968) ‘Urokinase inhibitor in human placenta’, Nature, 217, 253–4Google Scholar
  132. Kawano, T., Morimoto, K. and Iemura, Y. (1970) ‘Partial purification and properties of urokinase inhibitor from human placenta’, Journal of Biochemistry, 67, 333–42Google Scholar
  133. Kester, R.C. (1971) ‘The distribution of plasminogen activator in the male genital tract’, Journal of Clinical Pathology, 24, 726–31Google Scholar
  134. King, J.B. (1972) ‘Fibrinolysis in bile’, Thrombosis et Diathesis Haemorrhagica, 28, 299–305Google Scholar
  135. Klingemann, H.-G., Egbring, R., Holst, F., Gramse, M. and Havemann, K. (1981) ‘Digestion of ot2-antiplasmin inhibitor by neutral proteases from human leucocytes’, Thrombosis Research, 24, 479–83Google Scholar
  136. Kluft, C. (1976) ‘Occurrence of CI inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activity’, Haemostasis, 5, 136–46Google Scholar
  137. Kluft, C. (1977) ‘An inventory of plasminogen activators in human plasma’, Thrombosis and Haemostasis, 38, 134Google Scholar
  138. Kluft, C. (1978) ‘Cl-inactivator-resistant fibrinolytic activity in plasma euglobulin fractions: its relation to vascular activator in blood and its role in euglobulin fibrinolysis’, Thrombosis Research, 13, 135–51Google Scholar
  139. Kluft, C. (1979) ‘Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators’, Thrombosis and Haemostasis, 41, 365–83Google Scholar
  140. Kluft, C, Trumpi-Kalshoven, M.M. and Deelder, A.M. (1979) ‘Factor XII-independent activator generation in human plasma’, in J.F. Davidson, V. Cepelak, M.M. Samama and P.C. Desnoyers (eds.) Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 4, Churchill Livingstone, Edinburgh, pp. 362–7Google Scholar
  141. Kluft, C, Los, P. and Jie, A.F.H. (1981) ‘Assay and occurrence of two molecular forms of a?-antiplasmin in plasma’, Thrombosis and Haemostasis, 46, 281Google Scholar
  142. Kluft, C, Wijngaards, G. and Jie, A.F.H. (1981) ‘The factor XII-independent plasminogen proactivator system of plasma includes urokinase-related activity’, Thrombosis and Haemostasis, 46, 343Google Scholar
  143. Kok, P. (1979) ‘Separation of plasminogen activators from human uterine tissue and a comparison with activators from human urine and porcine tissue’, Thrombosis and Haemostasis, 41, 718–33Google Scholar
  144. Kok, P. and Astrup, T. (1969) ‘Isolation and purification of a tissue plasminogen activator and its comparison with urokinase’, Biochemistry, 8, 79–86Google Scholar
  145. Kopitar, M., Stegnar, M., Accetto, B. and Lopez, D. (1974) ‘Isolation and characterization of plasminogen activator from pig leucocytes’, Thrombosis et Diathesis Haemorrhagica, 31, 72–85Google Scholar
  146. Korninger, C. and Collen, D. (1981) ‘Inhibition of human tissue plasminogen activator by human plasma: no evidence for a specific antiactivator’, Thrombosis and Haemostasis, 46, 280Google Scholar
  147. Kruithof, E.K.O. and Bachmann, F. (1981) ‘Relative affinity of vascular and tissue plasminogen activator to fibrin and fibrinogen’, Thrombosis and Haemostasis, 46,163Google Scholar
  148. Kruithof, E.K.O., Ransijn, A. and Bachmann, F. (1982) ‘Inhibition of tissue plasminogen activator (TA) by human plasma’, Haemostasis 11, Suppl. 1, 60Google Scholar
  149. Künzer, W. and Haberhausen, A. (1963) ‘Fibrinolytic activity of human erythrocytes’, Nature, 198, 396–7Google Scholar
  150. Kwaan, H.C. and Astrup, T. (1963) ‘Localisation of fibrinolytic activity in the eye’, Archives of Pathology, 76, 595–601Google Scholar
  151. Laake, K. and Venneröd, A.M. (1974) ‘Factor XH-induced fibrinolysis: studies on the separation of prekallikrein, plasminogen proactivator and factor XI in human plasma’, Thrombosis Research, 4, 285–302Google Scholar
  152. Landmann, H. and Markwardt, F. (1970) ‘Irreversible synthetische Inhibitoren der Urokinase’, Experientia, 26, 145–7Google Scholar
  153. Lazarus, G.S., Daniels, J.R., Brown, R.S., Bladen, H.A. and Fullmer, H.M. (1968) ‘Degradation of collagen by a human granulocyte collagenolytic system’, Journal of Clinical Investigation, 47, 2622–9Google Scholar
  154. Lerch, P.G., Rickli, E.E., Lergier, W. and Gillessen, D. (1980) ‘Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties’, European Journal of Biochemistry, 107, 7–13Google Scholar
  155. Lesuk, A., Terminiello, L. and Traver, J.H. (1965) ‘Crystalline human urokinase: some properties’, Science, 147, 880–2Google Scholar
  156. Lesuk, A., Terminiello, L., Traver, J.H. and Groff, J.L. (1967) ‘Biochemical and biophysical studies of human urokinase’, Thrombosis et Diathesis Haemorrhagica, 18, 293–4Google Scholar
  157. Libeskind, I.C., Lipinski, B. and Gurewich, V. (1981) ‘Binding of blood plasminogen activator to fibrinogen, fibrin monomer and fibrin’, Thrombosis and Haemostasis, 46, 163Google Scholar
  158. Lijnen, H.R., Hoylaerts, M. and Collen, D. (1980) ‘Isolation and characterization of a glycoprotein with affinity for the lysine binding site (LBS) of plasminogen’, Journal of Biological Chemistry, 255, 10214–22Google Scholar
  159. Lijnen, H.R., Jacobs, G. and Collen, D. (1981a) ‘Histidine-rich glycoprotein in a normal and a clinical population’, Thrombosis Research, 22, 519–23Google Scholar
  160. Lijnen, H.R., De Cock, F. and Collen, D. (1981b) ‘Turnover of human histidine-rich glycoprotein in healthy subjects and during thrombolytic therapy’, Thrombosis Research, 23, 121–31Google Scholar
  161. Lijnen, H.R., Wiman, B., Van Hoef, B. and Collen, D. (1981c) ‘Partial primary structure of human a2-antiplasmin’, Thrombosis and Haemostasis, 46, 282Google Scholar
  162. Lijnen, H.R., Wiman, B. and Collen, D. (1982) ‘Comparison of the partial primary structure of human a2-antiplasmin with other plasma protease inhibitors’, Haemostasis, 11, Suppl. 1, 55Google Scholar
  163. Lloyd, D.A., Cederholm-Williams, S.A. and Sharp, A.A. (1981) ‘Binding of plasminogen and vascular plasminogen activator to fibrin and the fibrin alpha-chain’, Thrombosis and Haemostasis, 46, 163Google Scholar
  164. Lorand, L. and Mozen, M.M. (1964) ‘Esterhydrolysing activity of urokinase preparations’, Nature, 201, 392–3Google Scholar
  165. Lormeau, J.C, Goulay, J., Vairel, E.G. and Choay, J. (1977) ‘The action of urokinases on plasminogens’, Thrombosis and Haemostasis, 38, 257Google Scholar
  166. Loskutoff, D.J. (1977) ‘An inhibitor of plasminogen activator in endothelial cells’, Journal of Cell Biology, 75, 80aGoogle Scholar
  167. Loskutoff, D.J. (1981) ‘Effect of thrombin on the production of plasminogen activator by endothelial cells’, Thrombosis and Haemostasis, 46, 82Google Scholar
  168. Loskutoff, D.J. and Edgington, T.S. (1977) ‘Synthesis of a fibrinolytic activator and inhibitor by endothelial cells’, Proceedings of the National Academy of Sciences, 74, 3903–7Google Scholar
  169. Loskutoff, D.J. and Edgington, T.S. (1981) ‘An inhibitor of plasminogen activator in rabbit iendothelial cells’, Journal of Biological Chemistry, 256, 4142–5Google Scholar
  170. Loskutoff, D.J. and Gerna, M. (1982) ‘An inhibitor in rabbit endothelial cells that recognises urokinase-like but not tissue-type plasminogen activators’, Haemostasis, 11, Suppl. 1, 48Google Scholar
  171. Macfarlane, R.G. and Pilling, J. (1947) ‘Fibrinolytic activity of normal urine’, Nature, 159, 779Google Scholar
  172. Mackie, M., Booth, N.A. and Bennett, B. (1981) ‘Comparative studies on human activators of plasminogen’, British Journal of Haematology, 47, 77–90Google Scholar
  173. Mandle, R.J. and Kaplan, A.P. (1979) ‘Hageman-factor-dependent fibrinolysis: Generation of fibrinolytic activity in the interaction of human activated factor XI and plasminogen’, Blood, 54, 850–62Google Scholar
  174. Marder, V.J., Shulman, N.R. and Carroll, W.R. (1969) ‘High molecular weight derivatives of human fibrinogen produced by plasmin’, Journal of Biological Chemistry, 244, 2111–9Google Scholar
  175. Markus, G., De Pasquale, J.L. and Wissler, F.C. (1978) ‘Quantitative determination of the binding of i -aminoproic acid to native plasminogen’, Journal of Biological Chemistry, 253, 727–32Google Scholar
  176. McLellan, W.L., Vetterlein, D. and Roblin, R. (1980) ‘The glycoprotein nature of human plasminogen activators’, FEBS Letters, 115, 181–4Google Scholar
  177. Miller, L.L. and Bale, W.F. (1954) ‘Synthesis of all plasma protein fractions except gamma globulin by the liver. Use of zone electrophoresis and lysine-2-C14 to define plasma proteins synthesized by the isolated perfused liver’, Journal of Experimental Medicine, 99, 125–32Google Scholar
  178. Mirsky, I.A., Perisutti, G. and Davis, N.C. (1959) ‘Destruction of glucagon, adrenocorticotropin and somatotropin by human blood plasma’, Journal of Clinical Investigation, 38, 14–20Google Scholar
  179. Moore, S., Pepper, D.S. and Cash, J.D. (1975) ‘The isolation and characterization of a platelet-specific ß-globulin (ß-thromboglobulin) and the detection of anti-urokinase and antiplasmin released from thrombin-aggregated washed human platelets’, Biochimica et Biophysica Acta, 379, 360–9Google Scholar
  180. Moroi, M. and Aoki, N. (1976) ‘Isolation and characterization of a2-plasmin inhibitor from human plasma’, Journal of Biological Chemistry, 251, 5956–65Google Scholar
  181. Moroi, M. and Aoki, N. (1977) ‘Inhibition of proteases in coagulation, kinin-forming and complement systems by a9-plasmin inhibitor’, Journal of Biochemistry, 82, 969–72Google Scholar
  182. Moroz, L.A. (1977) ‘Increased blood fibrinolytic activity after aspirin ingestion’, New England Journal of Medicine, 296, 525–9Google Scholar
  183. Moroz, L.A. and Gilmore, N.J. (1976) ‘Fibrinolysis in normal plasma and blood: evidence for significant mechanisms independent of the plasminogen-plasmin system’, Blood, 48, 531–45Google Scholar
  184. Mounter, L.A. and Atiyeh, W. (1960) ‘Proteases of human leucocytes’, Blood, 15, 52–9Google Scholar
  185. Mui, P.T.K., James, H.L. and Ganguly, P. (1975) ‘Isolation and properties of a low molecular weight antiplasmin of human blood platelets and serum’, British Journal of Haematology, 29, 627–37Google Scholar
  186. Mullertz, S. (1953) ‘The action of plasmin on fibrin and fibrinogen in blood’, Acta Physiologica Scandinavica, 28, 29–40Google Scholar
  187. Mullertz, S. and Clemmensen, I. (1976) ‘The primary inhibitor of plasmin in human plasma’, Biochemical Journal, 159, 545–53Google Scholar
  188. Murano, G. and Aronson, D.L. (1979) ‘High and low molecular weight urokinase’, Thrombosis and Haemostasis, 42, 1066–8Google Scholar
  189. Murray, J., Crawford, G.P.M., Ogston, D. and Douglas, A.S. (1974) ‘Studies on an inhibitor of plasminogen activators in human platelets’, British Journal of Haematology, 26, 661–5Google Scholar
  190. Nachman, R.L. and Harpel, P.C. (1976) ‘Platelet a2-macroglobulin and a,-antitrypsin’, Journal of Biological Chemistry, 251, 4514–21Google Scholar
  191. Nanninga, L.B. and Guest, M.M. (1964) ‘On the interaction of fibrinolysin (plasmin) with the inhibitors antifibrinolysin and soy bean trypsin inhibitor’, Archives of Biochemistry and Biophysics, 108, 542–51Google Scholar
  192. Nieuwenhuizen, W., Wijngaards, G. and Groenvald, E. (1977) ‘Synthetic substrates and the discrimination between urokinase and tissue plasminogen activator activity’, Thrombosis Research, 11, 87–9Google Scholar
  193. Niewiarowski, S. and Prou-Wartelle, O. (1959) ‘Role du facteur contact (facteur Hageman) dans la fibrinolyse’, Thrombosis et Diathesis Haemorrhagica, 3, 593–603Google Scholar
  194. Nilsson, I., Cedergren, B. and Wiman, B. (1982) ‘On the significance of the two forms of human a2-antiplasmin with different affinity for the lysine-binding sites in plasminogen’, Haemostasis, 11, Suppl. 1, 62Google Scholar
  195. Nishimukai, H., Kera, Y., Sakata, K. and Yamasawa, K. (1981) ‘Genetic polymorphism of plasminogen: A new basic variant (PLG B) and population study in Japanese’, Vox Sanguinis, 40, 422–5Google Scholar
  196. Nolan, C, Hall, L.S., Barlow, G.H. and Tribby, U.E. (1977) ‘Plasminogen activator from human embryonic kidney cell cultures’, Biochimica et Biophysica Acta, 496, 384–400Google Scholar
  197. Noordhoek Hegt, V and Brakman, P. (1974) ‘Histochemical study of an inhibitor of fibrinolysis in the human arterial wall’, Nature, 248, 75–6Google Scholar
  198. Noren, I., Ramström, G. and Wallen, P. (1975) ‘Fibrin plate method with reagents purified by affinity chromatography and its use for determination of fibrinolytic and other proteolytic activity in saliva, bile and plasma’, Haemostasis, 4, 110–24Google Scholar
  199. Norman, P.S. and Hill, B.M. (1958) ‘Studies on the plasmin system. III. Physical properties of the two plasmin inhibitors in plasma’, Journal of Experimental Medicine, 108, 639–49Google Scholar
  200. Nussenweig, V., Seligmann, M., Pelmont, J. and Grabar, P. (1961) ‘Les produits de degradation du fibrinogene humain par la plasmin’, Annales de Tinstitut Pasteur, 100, 377–89Google Scholar
  201. Ogston, D., Ogston, C.M., Ratnoff, O.D. and Forbes, CD. (1969) ‘Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors’, Journal of Clinical Investigation, 48, 1786–801Google Scholar
  202. Ogston, D., Bennett, B., Herbert, R.J. and Douglas, A.S. (1973) ‘The inhibition of urokinase by a2-macroglobulin’, Clinical Science, 44, 73–9Google Scholar
  203. Ogston, D., Bennett, B. and Mackie, M. (1976) ‘Properties of a partially purified preparation of a circulating plasminogen activator’, Thrombosis Research, 8, 275–84Google Scholar
  204. Ohlsson, K. (1971) ‘Properties of leucocyte protease’, Clinica Chimica Acta, 32, 399–405Google Scholar
  205. Ohlsson, K. and Olsson, I. (1974) ‘The neutral proteases of human granulocytes. Isolation and partial characterization of granulocyte elastases’, European Journal of Biochemistry, 42, 519–27Google Scholar
  206. Okamoto, U., Nagamatsu, Y. and Matsumoto, M. (1974) ‘Studies on a plasminogen activating system in human milk. I. Isolation of plasminogen activator and proactivator from human milk, and estimation of their molecular weights’, Acta Haematologica Japonica, 37, 121–31Google Scholar
  207. Olexa, S.A., Budzynski, A.Z. and Marder, V.J. (1979) ‘Modification of high molecular weight plasmic degradation products of human crosslinked fibrin’, Biochimica et Biophysica Acta, 576, 39–50Google Scholar
  208. Ong, E.B., Johnson, A.J. and Schoellmann, G. (1976) ‘Identification of an active site histidine in urokinase’, Biochimica et Biophysica Acta, 429, 252–7Google Scholar
  209. Ong, E.B., Soberano, M.E., Johnson, A.J. and Schoellmann, G. (1977) ‘Studies on the biochemistry of urokinase’, Thrombosis and Haemostasis, 38, 801–8Google Scholar
  210. Opie, E.L. (1907) ‘Experimental pleurisy. Resolution of a fibrinous exudate’, Journal of Experimental Medicine, 9, 391Google Scholar
  211. Oshiba, S. and Schonfield, L.J. (1970) ‘Plasminogen activator in bile stimulated by sodium taurcholate in isolated hamster livers’, Proceedings of the Society for Experimental Biology and Medicine, 133, 89–92Google Scholar
  212. Oshiba, S., Hata, S. and Okamoto, S. (1969) ‘A plasminogen activator in mammalian bile’, Japanese Journal of Physiology, 19, 212–9Google Scholar
  213. Oshiba, S., Ariga, T., Sawai, H. and lmai, H. (1977) ‘Some aspects of biliary fibrinolysis’, Thrombosis and Haemostasis, 38, 273Google Scholar
  214. den Ottolander, G.J.H., Leijnse, B. and Cremer-Elf rink, H.M.J. (1967) ‘Plasmatic and platelet antiplasmins and anti-activators’, Thrombosis et Diathesis Haemorrhagica, 18, 404–15Google Scholar
  215. den Ottolander, G.J.H., Leijnse, B. and Cremer-Elfrink, H.M.J. (1969) ‘Plasmatic and thrombocytic antiplasmins and anti-activators. II’, Thrombosis et Diathesis Haemorrhagica, 21, 26–34Google Scholar
  216. Painter, R.H. and Charles, A.F. (1962) ‘Characterization of a soluble plasminogen activator from kidney cell cultures’, American Journal of Physiology, 202, 1125–30Google Scholar
  217. Pandolfi, M. and Astrup, T. (1967) ‘A histochemical study of the fibrinolytic activity. Cornea, conjunctiva, and lacrimal gland’, Archives of Ophthalmology, 77, 258–64Google Scholar
  218. Pandolfi, M. and Kwaan, H.C. (1967) ‘Fibrinolysis in the anterior segment of the eye’, Archives of Ophthalmology, 77, 99–104Google Scholar
  219. Pandolfi, M., Nilsson, I.M. and Robertson, B. (1967) ‘Fibrinolytic activity of human veins’, Lancet, ii, 127–128Google Scholar
  220. Pasquini, R. and Hershgold, E.J. (1973) ‘Effects of plasmin on human factor VIII (AHF)’, Blood, 41, 105–11Google Scholar
  221. Pepper, D.S. and Allen, R. (1978) ‘Isolation and characterization of human cadaver vascular endothelial activator’, in J.F. Davidson, R.M. Rowan, M.M. Samama and P.C. Desnoyers (eds.) Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3, Raven Press, New York, pp. 91–8Google Scholar
  222. Petkov, D., Christova, E. and Karadjova, M. (1973) ‘Amidase activity of urokinase I. Hydrolysis of a-/V-acetyl-L-lysine?-nitroanilide’, Thrombosis et Diathesis Haemorrhagica, 29, 276–85Google Scholar
  223. Pillemer, L., Ratnoff, O.D., Blum, L. and Lepow, I.H. (1953) ‘The inactivation of complement and its components by plasmin’, Journal of Experimental Medicine, 97, 573–89Google Scholar
  224. Pizzo, S.V., Schwartz, M.L., Hill, R.L. and McKee, P.A. (1972) ‘The effect of plasmin on the subunit structure of human fibrinogen’, Journal of Biological Chemistry, 247, 636–45Google Scholar
  225. Pizzo, S.V., Taylor, L.M., Schwartz, M.L., Hill, R.L. and McKee, P.A. (1973) ‘Subunit structure of fragment D from fibrinogen and crosslinked fibrin’, Journal of Biological Chemistry, 248, 4584–90Google Scholar
  226. Plow, E.F. (1980) ‘The major fibrinolytic proteases of human leucocytes’, Biochimica et Biophysica Acta, 630, 47–56Google Scholar
  227. Plow, E.F. (1982) ‘Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway’, Journal of Clinical Investigation, 69, 564–72Google Scholar
  228. Plow, E.F. and Collen, D. (1981) ‘Presence and release of a2-antiplasmin from human platelets’, Blood, 58, 1069–74Google Scholar
  229. Plow, E.F. and Edgington, T.S. (1975) ‘An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leucocyte proteases at physiologic pH’, Journal of Clinical Investigation, 56, 30–8Google Scholar
  230. Prokopowicz, J. and Stormorken, H. (1968) ‘Fibrinolytic activity of leucocytes in smears of bone marrow and peripheral blood’, Scandinavian Journal of Haematology, 5, 129–37Google Scholar
  231. Prokopowicz, J., Rejniak, L. and Niewiarowski, S. (1967) ‘Influence of cytostatic agents on fibrinolytic and proteolytic enzymes and on phagocytosis of guinea-pig leucocytes’, Experientia, 23, 813–4Google Scholar
  232. Propping, D., Zaneveld, L.J.D., Tauber, P.F. and Schumacher, G.F.B. (1978) ‘Purification of plasminogen activators from human seminal plasma’, Biochemical Journal, 171, 435–44Google Scholar
  233. Rabiner, S.F., Goldfine, I.D., Hart, A., Summaria, L. and Robbins, K.C. (1969) ‘Radioimmunoassay of human plasminogen and plasmin’, Journal of Laboratory and Clinical Medicine, 74, 265–73Google Scholar
  234. Radcliffe, R. and Heinze, T. (1978) ‘Isolation of plasminogen activator from human plasma by chromatography on lysine-Sepharose’, Archives of Biochemistry and Biophysics, 189, 185–94Google Scholar
  235. Räköczi, I., Wiman, B. and Collen, D. (1978) ‘On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin’, Biochimica et Biophysica Acta, 540, 295–300Google Scholar
  236. Ränby, M. (1982) ‘Studies on the kinetics of plasminogen activation by tissue plasminogen activator’, Biochimica et Biophysica Acta, 704, 461–9Google Scholar
  237. Ratnoff, O.D., Pensky, J., Ogston, D. and Naff, G.B. (1969) ‘The inhibition of plasmin, plasma kallikrein, plasma permeability factor and the C’lr subcomponent of the first component of complement by C’l esterase inhibitor’, Journal of Experimental Medicine, 129, 315–31Google Scholar
  238. Raum, D., Marcus, D. and Alper, C.A. (1980) ‘Genetic polymorphism of human plasminogen’, American Journal of Human Genetics, 32, 681–9Google Scholar
  239. Raum, D., Marcus, D., Alper, C.A., Levey, R., Taylor, P.D. and Starzl, T.E. (1980) ‘Synthesis of human plasminogen by the liver’, Science, 208, 1036–7Google Scholar
  240. Rickli, E.E. and Zaugg, H. (1970) ‘Isolation and purification of highly enriched tissue plasminogen activator from pig heart’, Thrombosis et Diathesis Haemorrhagica, 23, 64–76Google Scholar
  241. Rijken, D.C. and Collen, D. (1981) ‘Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture’, Journal of Biological Chemistry, 256, 7035–41Google Scholar
  242. Rijken, D.C, Wijngaards, G., Zaal-De Jong, M. and Welbergen, J. (1979) ‘Purification and partial characterization of plasminogen activator from human uterine tissue’, Biochimica et Biophysica Acta, 580, 140–53Google Scholar
  243. Rijken, D.C, Wijngaards, G. and Welbergen, J. (1980) ‘Relationship between tissue plasminogen activator and the activators in blood and vascular wall’, Thrombosis Research, 18, 815–30Google Scholar
  244. Rijken, D.C, Hoylaerts, M. and Collen, D. (1981a) ‘On the fibrinolytic properties of single-chain and two-chain human tissue plasminogen activator’, Thrombosis and Haemostasis, 46, 12Google Scholar
  245. Rijken, D.C, Wijngaards, G. and Welbergen, J. (1981b) ‘Immunological characterization of plasminogen activator activities in human tissues and body fluids’, Journal of Laboratory and Clinical Medicine, 97, 477–86Google Scholar
  246. Rimon, A., Shamash, Y. and Shapiro, B. (1966) ‘The plasmin inhibitor of human plasma. IV. Its action on plasmin, trypsin, chymotrypsin and thrombin’, Journal of Biological Chemistry, 241, 5102–7Google Scholar
  247. Robbins, K.C, Summaria, L., Elwyn, D. and Barlow, G.H. (1965) ‘Further studies on the purification and characterization of human plasminogen and plasmin’, Journal of Biological Chemistry, 240, 541–50Google Scholar
  248. Robbins, K.C, Summaria, L., Hsieh, B. and Shah, R.J. (1967) ‘The peptide chains of human plasmin. Mechanism of activation of human plasminogen’, Journal of Biological Chemistry, 242, 2333–42Google Scholar
  249. Robertson, B.R., Pandolfi, M. and Nilsson, I.M. (1972) ‘“Fibrinolytic capacity” in healthy volunteers as estimated from effect of venous occlusion of arms’, Acta Chirurgica Scandinavica, 138, 429–36Google Scholar
  250. Rosing, D.R., Redwood, D.R., Brakman, P., Astrup, T. and Epstein, S.E. (1978) ‘The fibrinolytic response of man to vasoactive drugs measured in arterial blood’, Thrombosis Research, 13, 419–28Google Scholar
  251. Rulot, H. (1904) ‘Intervention des leucocytes dans l’autolyse de la fibrine (fibrinolyse de Dastre)’, Archives Internationales de Physiologie, 1, 152–8Google Scholar
  252. Sahli, W. (1885) ‘Ueber das Vorkommen von Pepsin und Trypsin im normalen menschlichen Hara’, Pflugers Archiv fur Physiologie, 36, 209–29Google Scholar
  253. Saito, H., Ratnoff, O.D., Waldmann, R. and Abraham, J.P. (1975) ‘Fitzgerald trait: deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinin and the property of diluted plasma enhancing vascular permeability (PF/Dil)’, Journal of Clinical Investigation, 55, 1082–9Google Scholar
  254. Saito, H., Goldsmith, G.H., Moroi, M. and Aoki, N. (1979) ‘Inhibitory spectrum of oc2-plasmin inhibitor’, Proceedings of the National Academy of Sciences, 76, 2013–7Google Scholar
  255. Saito, H., Goodenough, L.T., Knowles, B.B. and Aden, D.P. (1982) ‘Synthesis and secretion of a2-plasmin inhibitor by established human liver cell lines’, Proceedings of the National Academy of Sciences, 79, 5684–7Google Scholar
  256. Sakata, Y. and Aoki, N. (1980) ‘Cross-linking of a2-plasmin inhibitor to fibrin by fibrin-stabilizing factor’, Journal of Clinical Investigation, 65, 290–7Google Scholar
  257. Sakata, Y. and Aoki, N. (1982) ‘Significance of cross-linking of ot2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis’, Journal of Clinical Investigation, 69, 536–42Google Scholar
  258. Sandjberg Hansen, M. and Clemmensen, I. (1980) ‘Partial purification and characterization of a new fast-acting plasmin inhibitor from human platelets’, Biochemical Journal, 187, 173–80Google Scholar
  259. Sawyer, W.D., Fletcher, A.P., Alkjaersig, N. and Sherry, S. (1960) ‘Studies on the thrombolytic activity of human plasma’, Journal of Clinical Investigation, 39, 426–34Google Scholar
  260. Schaller, J., Nick, H., Rickli, E., Gillessen, D., Lergier, W. and Studer, R.O. (1982) ‘The two chain structure of human low molecular weight (LMW) urinary urokinase, evidenced by sequence analysis’, Haemostasis, 11, Suppl. 1, 54Google Scholar
  261. Schmidt, W. and Havemann, K. (1974) ‘Isolation of elastase-like and chymotrypsin-like neutral proteases from human granulocytes’, Hoppe-Seyler’s Zeitschrift fur Physiologische Chemie, 355, 1077–82Google Scholar
  262. Schreiber, A.D., Kaplan, A.P. and Austen, K.F. (1973) ‘Inhibition by CI 1NH of Hagemann factor fragment activation of coagulation, fibrinolysis and kinin generation’, Journal of Clinical Investigation, 52, 1402–9Google Scholar
  263. Schwick, H.G., Heimburger, N. and Haupt, H. (1967) ‘Purification and chemical-physical properties of some proteinase inhibitors of plasma’, Thrombosis et Diathesis Haemorrhagica, 18, 302Google Scholar
  264. Seigel-Ralston, A. and Astrup, T. (1972) ‘A previously undescribed fibrinolysis inhibitor in human blood’, Nature, 234, 180–1Google Scholar
  265. Semar, M., Skoza, I. and Johnson, A.J. (1969) ‘Partial purification and properties of a plasminogen activator from human erythrocytes’, Journal of Clinical Investigation, 48, 1777–85Google Scholar
  266. Semeraro, N., Colucci, M., Telesforo, P. and Collen, D. (1978) ‘The inhibition of plasmin by antithrombin-heparin complex. I. In human plasma in vitro’, British Journal of Haematology, 39, 91–9Google Scholar
  267. Sherman, L.A., Lee, J. and Stewart, C.C. (1977) ‘Release of fibrinolytic enzymes by macrophages in response to soluble fibrin’, Thrombosis and Haemostasis, 38, 46Google Scholar
  268. Sherry, S. and Alkjaersig, N. (1957) ‘Studies on the fibrinolytic enzyme of human plasma’, Thrombosis et Diathesis Haemorrhagica, 1, 264–76Google Scholar
  269. Sherry, S., Lindemeyer, R.L, Fletcher, A.P. and Alkjaersig, N. (1959) ‘Studies on enhanced fibrinolytic activity in man’, Journal of Clinical Investigation, 38, 810–22Google Scholar
  270. Sherry, S., Alkjaersig, N. and Fletcher, A.P. (1964) ‘Assay of urokinase preparations with the synthetic substrate acetyl-L-lysine methyl ester’, Journal of Laboratory and Clinical Medicine, 64, 145–53Google Scholar
  271. Sjöholm, I., Wiman, B. and Wallen, P. (1973) ‘Studies on the conformational changes of plasminogen induced during activation to plasmin and by 6-amino-hexanoic acid’, European Journal of Biochemistry, 39, 471–9Google Scholar
  272. Sobel, G.W., Möhler, S.R., Jones, N.W., Dowdy, A.B.C. and Guest, M.M. (1952) ‘Urokinase: an activator of plasma Profibrinolysin extracted from urine’, American Journal of Physiology, 171, 768–9Google Scholar
  273. Soberano, M.E., Ong, E.B. and Johnson, A.J. (1976a) ‘The effects of inhibitors on the catalytic conversion of urokinase’, Thrombosis Research, 9, 675–81Google Scholar
  274. Soberano, M.E., Ong, E.B., Johnson, A.J., Levy, M. and Schoellmann, G. (1976b) ‘Purification and characterization of two forms of urokinase’, Biochimica et Biophysica Acta, 445, 763–73Google Scholar
  275. Sottrup-Jensen, L., Claeys, H., Zajdel, M., Petersen, T.E. and Magnusson, S. (1978) ‘The primary structure of human plasminogen: isolation of two lysine-binding fragments and one “mini”-plasminogen (MW 38,000) by elastase-catalyzed-specific limited proteolysis’, in J.F. Davidson, R.M. Rowan, M.M. Samama and P.C. Desnoyers (eds.) Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3, Raven Press, New York, pp. 191–209Google Scholar
  276. Sottrup-Jensen, L., Hansen, H.F., Mortensen, S.B., Petersen, T.E., Magnusson, S. and Jörnvall, H. (1981) ‘Mechanism of proteinase-binding to a2-macroglobulin’, Thrombosis and Haemostasis, 46, 87Google Scholar
  277. Stefanini, M. and Murphy, l.S. (1956) ‘Studies on platelets. XIV. Human platelets as a source of antifibrinolysin’, Journal of Clinical Investigation, 35, 355–61Google Scholar
  278. Steinbuch, M. (1971) ‘Les antiproteases du plasma’, Revue Francaise de Transfusion, 14, 61–82Google Scholar
  279. Storm, O. (1955) ‘Fibrinolytic activity in human tears’, Scandinavian Journal of Clinical and Laboratory Investigation, 7, 55–8Google Scholar
  280. Summaria, L., Hsieh, B., Groskopf, W.R. and Robbins, K.C. (1967) ‘The isolation and characterisation of the S-carboxymethyl ß (light) chain derivative of human plasmin’, Journal of Biological Chemistry, 242, 5046–52Google Scholar
  281. Summaria, L., Robbins, K.C. and Barlow, G.H. (1971) ‘Isolation and characterization of the S-carboxymethyl heavy chain derivative of human plasmin’, Journal of Biological Chemistry, 246, 2143–6Google Scholar
  282. Summaria, L., Arzadon, L., Berabe, P. and Robbins, K.C. (1972) ‘Studies on the isolation of the multiple molecular forms of human plasminogen and plasmin by isoelectric focusing methods’, Journal of Biological Chemistry, 247, 4691–702Google Scholar
  283. Summaria, L., Arzadon, L., Berabe, P. and Robbins, K.C. (1975) ‘The activation of plasminogen to plasmin by urokinase in the presence of the plasmin inhibitor Trasylol’, Journal of Biological Chemistry, 250, 3988–95Google Scholar
  284. Summaria, L., Spitz, F., Arzadon, L., Boreisha, G. and Robbins, K.C. (1976) ‘Isolation and characterization of the affinity chromatography forms of human glu- and lysplasminogens and plasmins’, Journal of Biological Chemistry, 251, 3693–9Google Scholar
  285. Summaria, L., Boreisha, I.G., Arzadon, L. and Robbins, K.C. (1977) ‘Activation of human gluplasminogen to glu-plasmin by urokinase in presence of plasmin inhibitors’, Journal of Biological Chemistry, 252, 3945–51Google Scholar
  286. Takagi, T. and Doolittle, R.F. (1975a) ‘Amino acid sequence studies on plasmin-derived fragments of human fibrinogen: amino-terminal sequences of intermediate and terminal fragments’, Biochemistry, 14, 940–6Google Scholar
  287. Takagi, T. and Doolittle, R.F. (1975b) ‘Amino acid studies on the a-chain of human fibrinogen. Location of four plasmin attack points and a covalent cross-linking site’, Biochemistry, 14, 5149–56Google Scholar
  288. Thorsen, S. (1973) ‘The inhibition of tissue plasminogen activator and urokinase-induced fibrinolysis by some natural proteinase inhibitors and by plasma and serum from normal and pregnant subjects’, Scandinavian Journal of Clinical and Laboratory Investigation, 31, 57–9Google Scholar
  289. Thorsen, S. (1975) ‘Difference in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of (d-aminocarboxylic acids’, Biochimica et Biophysica Acta, 393, 55–65Google Scholar
  290. Thorsen, S., Glas-Greenwalt, P. and Astrup, T. (1972) ‘Differences in the binding to fibrin of urokinase and tissue plasminogen activator’, Thrombosis et Diathesis Haemorrhagica, 28, 65–74Google Scholar
  291. Thorsen, S., Clemmensen, I., Sottrup-Jensen, L. and Magnusson, S. (1981) ‘Adsorption to fibrin of native fragments of known primary structure from human plasminogen’, Biochimica et Biophysica Acta, 668, 311–315Google Scholar
  292. Tissot, J.-D., Schneider, Ph. and Bachmann, F. (1982) ‘Isolation from human plasma of a plasminogen activator (PA) identical to urinary high Mrurokinase’, Haemostasis, 11, Suppl. 1, 7Google Scholar
  293. Todd, A.S. (1959) ‘The histological localisation of fibrinolysin activator’, Journal of Pathology and Bacteriology, 78, 281–3Google Scholar
  294. Trexler, M., Vali, Z. and Patthy, L. (1982) ‘Structure of the (o-amino-carboxylic binding sites of human plasminogen. Arginine 70 and aspartic acid 56 are essential for binding of ligand by kringle 4’, Journal of Biological Chemistry, 257, 7401–6Google Scholar
  295. Troll, W., Sherry, S. and Wachman, J. (1954) ‘The action of plasmin on synthetic substrates’, Journal of Biological Chemistry, 208, 85–93Google Scholar
  296. Trumpi-Kaishoven, M.M. (1978) ‘The relevance of CI inhibitor in the inhibition of the fibrinolytic activity of plasmin’, in J.F. Davidson, R.M. Rowan, M.M. Samama and P.C. Desnoyers (eds.) Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 3, Raven Press, New York, pp. 257–67Google Scholar
  297. Unkeless, J.C, Gordon, S. and Reich, E. (1974) ‘Secretion of plasminogen activator by stimulated macrophages’, Journal of Experimental Medicine, 139, 834–50Google Scholar
  298. Uszynski, M. (1980) ‘Isolation of peptides with anti-urokinase activity from the human placenta’, Thrombosis and Haemostasis, 42, 1411–6Google Scholar
  299. Uszynski, M. and Abildgaard, U. (1971) ‘Separation and characterization of two fibrinolytic inhibitors from human placenta’, Thrombosis et Diathesis Haemorrhagica, 25, 580–9Google Scholar
  300. Vali, Z. and Patthy, L. (1982) ‘Location of the intermediate and high affinity (o-aminocarboxylic acid-binding sites in human plasminogen’, Journal of Biological Chemistry, 257, 2104–10Google Scholar
  301. Vassalli, J.-D., Hamilton, J. and Reich, E. (1976) ‘Macrophage plasminogen activator: modulation of enzyme production by anti-inflammatory steroids, mitotic inhibitors, and cyclic nucleotides’, Cell, 8, 271–81Google Scholar
  302. Venneröd, A.M. and Laake, K. (1976) ‘Prekallikrein and plasminogen proactivator: absence of plasminogen proactivator in Fletcher factor deficient plasma’, Thrombosis Research, 8, 519–22Google Scholar
  303. Vetterlein, D., Young, P.L., Bell, T.E. and Roblin, R. (1979) ‘Immunological characterization of multiple molecular weight forms of human cell plasminogen activators’, Journal of Biological Chemistry, 254, 575–8Google Scholar
  304. Vetterlein, D., Bell, T.E., Young, P.L. and Roblin, R. (1980) ‘Immunological quantitation and immunoadsorption of urokinase-like plasminogen activators secreted by human cells’, Journal of Biological Chemistry, 255, 3665–72Google Scholar
  305. Violand, B.N. and Castellino, F.J. (1976) ‘Mechanism of the urokinase-catalyzed activation of human plasminogen’, Journal of Biological Chemistry, 25, 3906–12Google Scholar
  306. Violand, B.N., Sodetz, J.M. and Castellino, F.J. (1975) ‘The effect of 6-amino caproic acid on the gross conformation of plasminogen and plasmin’, Archives of Biochemistry and Biophysics, 170, 300–5Google Scholar
  307. Walker, J.E. and Ogston, D. (1982) ‘The inhibition of tissue activator and urokinase by human plasma’, Thrombosis and Haemostasis, 47, 265–8Google Scholar
  308. Wallen, P. and Iwanaga, S. (1968) ‘Differences between plasmic and tryptic digests of human S-sulpho-fibrinogen’, Biochimica et Biophysica Acta, 154, 414–7Google Scholar
  309. Wallen, P. and Ränby, M. (1977) ‘Purification and some properties of tissue plasminogen activator’, Thrombosis and Haemostasis, 38, 61Google Scholar
  310. Wallen, P. and Wiman, B. (1970) ‘Characterization of human plasminogen. I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations’, Biochimica et Biophysica Acta, 221, 20–30Google Scholar
  311. Wallen, P. and Wiman, B. (1975) ‘Purification of tissue activator using affinity chromatography. Effect of fibrin on the enzymatic properties of the activator’, Thrombosis et Diathesis Haemorrhagica, 34, 609Google Scholar
  312. Wallen, P., Ränby, M., Bergsdorf, N. and Kok, P. (1981) ‘Purification and characterization of tissue plasminogen activator. On the occurrence of two different forms and their enzymatic properties’, in J.F. Davidson, I.M. Nilsson and B. Astedt (eds.) Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 5, Churchill Livingstone, Edinburgh, pp. 16–23Google Scholar
  313. Walther, P.J., Steinmann, H.H., Hill, R.M. and McKee, P.A. (1974) ‘Activation of human plasminogen by urokinase. Partial characterization of a pre-activation peptide’, Journal of Biological Chemistry, 249, 1173–81Google Scholar
  314. Walton, P.L. (1967) ‘The hydrolysis of a-N-acetylglycyl-L-lysine methyl ester by urokinase’, Biochimica et Biophysica Acta, 132, 104–14Google Scholar
  315. Weinstein, M.J. and Doolittle, R.F. (1972) ‘Differential specificities of thrombin, plasmin and trypsin with regard to synthetic and natural substrates and inhibitors’, Biochimica et Biophysica Acta, 255, 577–90Google Scholar
  316. Weiss, A.S., Gallin, J.I. and Kaplan, A.P. (1974) ‘Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation’, Journal of Clinical Investigation, 53, 622–33Google Scholar
  317. White, W.F., Barlow, G.H. and Mozen, M.M. (1966) ‘The isolation and characterization of plasminogen activators (urokinase) from human urine’, Biochemistry, 5, 2160–9Google Scholar
  318. Wijngaards, G. and Bernik, M.B. (1981) ‘Activation and “inactivation” of a plasminogen proactivator (preurokinase) in human tissue culture media’, Thrombosis and Haemostasis, 46, 10Google Scholar
  319. Williams, J.R.B. (1951) ‘The fibrinolytic activity of urine’, British Journal of Experimental Pathology, 32, 530–7Google Scholar
  320. Wilson, E.L., Becker, M.L.B., Hoal, E.G. and Dowdle, E.B. (1980) ‘Molecular species of plasminogen activators secreted by normal and neoplastic human cells’, Cancer Research, 40, 933–8Google Scholar
  321. Wiman, B. (1977) ‘Primary structure of the B-chain of human plasmin’, European Journal of Biochemistry, 76, 129–37Google Scholar
  322. Wiman, B. (1978) ‘Biochemistry of the plasminogen to plasmin conversion’, in P.J. Gaffney and S. Balkuv-Ulutin (eds.) Fibrinolysis: Current Fundamental and Clinical Concepts, Academic Press, London, pp. 47–60Google Scholar
  323. Wiman, B. and Collen, D. (1977) ‘Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor’, European Journal of Biochemistry, 78, 19–26Google Scholar
  324. Wiman, B. and Collen, D. (1978a) ‘On the kinetics of the reaction between human antiplasmin and plasmin’, European Journal of Biochemistry, 84, 573–8Google Scholar
  325. Wiman, B. and Collen, D. (1978b) ‘Molecular mechanism of physiological fibrinolysis’, Nature, 272, 549–50Google Scholar
  326. Wiman, B. and Collen, D. (1979) ‘On the mechanism of the reaction between human oc9-antiplasmin and plasmin’, Journal of Biological Chemistry, 254, 9291–7Google Scholar
  327. Wiman, B. and Wallen, P. (1973) ‘Activation of human plasminogen by an insoluble derivative of urokinase. Structural changes of plasminogen in the course of activation to plasmin and demonstration of a possible intermediate compound’, European Journal of Biochemistry, 36, 25–31Google Scholar
  328. Wiman, B. and Wallen, P. (1975a) ‘On the primary structure of human plasminogen and plasmin. Purification and characterization of cyanogen-bromide fragments’, European Journal of Biochemistry, 57, 387–94Google Scholar
  329. Wiman, B. and Wallen, P. (1975b) ‘Structural relationships between “glutamic acid” and “lysine” forms of human plasminogen and their interaction with the NH2-terminal activation peptide as studied by affinity chromatography’, European Journal of Biochemistry, 50, 489–94Google Scholar
  330. Wiman, B. and Wallen, P. (1977) ‘The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen’, Thrombosis Research, 10, 213–22Google Scholar
  331. Wiman, B., Boman, L. and Collen, D. (1978) ‘On the kinetics of the reaction between human antiplasmin and a low-molecular-weight form of plasmin’, European Journal of Biochemistry, 87, 143–6Google Scholar
  332. Wiman, B., Lijnen, H.R. and Collen, D. (1979) ‘On the specific interaction between the lysine-binding sites in plasmin and complementary sites in a 2-antiplasmin and in fibrinogen’, Biochimica et Biophysica Acta, 579, 142–54Google Scholar
  333. Wun, T.-C, Schleuning, W.-D. and Reich, E. (1982) ‘Isolation and characterization of urokinase from human plasma’, Journal of Biological Chemistry, 257, 3276–83Google Scholar

Copyright information

© Derek Ogston 1983

Authors and Affiliations

  • Derek Ogston
    • 1
  1. 1.University of AberdeenUK

Personalised recommendations